NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
- Mechanism
- Curator reviewed
NBI-6024 is designed specifically to generate an immune response that could result in preservation of beta-islet cell function in patients with Type I diabetes or juvenile-onset diabetes. Because there is progressive beta-islet destruction in Type I diabetes, an early intervention strategy with a product like NBI-6024 could delay or prevent insulin dependence.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications.Curator reviewed
- Code names
- NBI-6024
Resolves to
What you can answer from here — as of April 02, 2025
Which companies are running trials of NBI-6024, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account